Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.
MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.
MacDonagh L, et al. Among authors: breen e.
Oncotarget. 2017 Aug 3;8(42):72544-72563. doi: 10.18632/oncotarget.19881. eCollection 2017 Sep 22.
Oncotarget. 2017.
PMID: 29069808
Free PMC article.